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Cardiac mitochondria may become dysfunctional during ischaemia, thus compromising cardiomyocyte function. Carvedilol is an a1/h-
adrenoceptor antagonist with antioxidant, neuroprotective, cardioprotective and vascularprotective properties, and is used to treat
hypertension, myocardial ischaemia and congestive heart failure. However, its impact on mitochondrial function during acute prolonged
ischaemia is unknown. We aimed to study the effect of carvedilol on cardiac mitochondrial function during acute ischaemia, using Wistar rat
hearts perfused with a Langendorff system, and then submitted to ischaemia in the presence and absence of carvedilol. We determined the
electrical potential of the mitochondrial membrane, O2 consumption by the respiratory chain, energy charge and the activity of the
mitochondrial respiratory chain complexes. In our model, carvedilol had a preferential action on phosphorylation, increasing the
mitochondrial energy charge (0.76F 0.03 vs. 0.65F 0.01 arbitrary units; P< 0.05) and decreasing the phosphorylation lag phase
(28.64F 4.23 vs. 62.4F 11.63 s; P < 0.05) during ischaemia. The larger amount of energy available allowed the preservation of the electrical
potential (201.2F 2.45 vs. 186.66F 3.36 mV;P< 0.05), thus improving mitochondrial function during acute prolonged ischaemia.
D 2003 Elsevier B.V. All rights reserved.Keywords: Ischaemia; Carvedilol; Mitochondrion1. Introduction
In Western countries, ischaemic heart disease is one of
the leading causes of morbidity and mortality. Although this
pathology has been recognised for centuries, only recently
have we started to understand its cellular and molecular
basis. During cardiac ischaemia, there is a relative or
absolute shortage of oxygen and nutrients in cardiomyo-
cytes, resulting in an impairment of energy production by
the mitochondria. Without energy, the proper structure and
function of cardiomyocytes and their components are at
risk.0014-2999/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2003.09.042
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E-mail address: lgoncalv@ci.uc.pt (L.M. Goncalves).Energy shortage and, therefore, cardiac mitochondria are
at the centre of the metabolic dysfunctions induced by
ischaemia. Thus, it is important to develop and use drugs
able to preserve the mitochondrial energy production during
ischaemia.
Carvedilol is a h- and a1-adrenoceptor antagonist. These
unique combined properties make it a vasodilator (increas-
ing coronary blood flow) and a negative inotrope (reducing
cardiac contractility)—both these actions are useful to
reduce the negative impact of ischaemia on cardiac metab-
olism. Carvedilol is currently used to treat hypertension
(Dunn et al., 1997; Feuerstein and Ruffolo, 1995; Noguchi
et al., 2000), myocardial ischaemia (Ryan et al., 1999) and
congestive heart failure (Cleland and McGowan, 1999;
Cleland et al., 1999; Colucci et al., 1996; Dargie, 2000,
2001; Dargie et al., 1999; Feuerstein et al., 1998; Packer et
al., 1996, 2001). Several authors have already shown that
this drug has neuroprotective (Lysko et al., 1992a,b; Yue et
al., 1994a), cardioprotective (Feuerstein et al., 1993; Yaoita
et al., 2002) and vascularprotective (Yue et al., 1993, 1994b)
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antioxidant (Yue et al., 1992). In animal models, carvedilol
was able to markedly decrease the area of infarct, mainly in
those models where it is known that the production of
reactive oxygen species is important to induce and expand
an area of acute ischaemia (Ruffolo et al., 1993).
These positive findings also occurred in human studies.
CAPRICORN (Carvedilol Post infarct survival Control in
left ventricular dysfunction) was a large clinical trial (1959
patients) that studied the impact of carvedilol (6.25 mg bid,
uptitrated to 25 mg bid) on the mortality and morbidity of
patients with left ventricular dysfunction after an acute
myocardial infarction; treatment was initiated before hospi-
tal discharge and less than 21 days after acute myocardial
infarction (Cleland et al., 1999; Dargie, 2000; Dargie et al.,
1999). In this study, patients treated with carvedilol showed
a significant decrease in total mortality, cardiovascular
mortality and nonfatal reinfarction (Dargie, 2001). Howev-
er, the ultrastructural basis of the positive effect of carvedilol
on ischaemic hearts is still to be completely determined. We
hypothesised that at least part of the results shown by
carvedilol in clinical trials involving patients with coronary
artery disease are due to a positive impact on mitochondrial
energy production during episodes of ischaemia.
Our work had, therefore, the objective of studying the
influence of carvedilol on the mitochondrial function of rat
hearts exposed to acute ischaemia, using an ex vivo model
of perfusion with a Langendorff system. Our hypothesis was
that carvedilol may prevent mitochondrial damage, thus
allowing the myocyte to be supplied with mitochondrial
ATP after the ischaemic period.2. Material and methods
This investigation conformed with the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health-NIH publication No. 85-23,
revised 1996-(National Research Council, 1996) and it was
approved by the Ethics Committee of the Centre for Neuro-
science and Cell Biology of Coimbra, where the experimen-
tal work took place. All compounds were of the purest
quality available and were ordered from Sigma (St. Louis,
MO) or Merck (Darmstadt, Germany), except for carvedilol,
which was obtained from Roche Diagnostics (Mannheim).
2.1. Experimental groups
Thirty Wistar rats were randomly assigned into three
experimental groups: control (n = 10), ischaemia (n = 10)
and ischaemia + carvedilol 40 AM (n = 10).
2.2. Assembly of the ex vivo perfusion system
Wistar rats, weighing around 300 g, were killed by CO2
inhalation. Each heart was rapidly excised and mounted in aLangendorff perfusion apparatus (model UP-100 from Hugo
Sachs Elektronik, Germany), and then perfused at a constant
flow (25 ml/min) with a Krebs modified solution (NaCl 118
mM, KCl 4.7 mM, KH2PO4 1.2 mM, NaHCO3 25 mM,
MgSO4 1.2 mM, Na2EDTA 0.5 mM, Glucose 10 mM and
CaCl2 3 mM; pH 7.4), gassed with carbogen (95% O2–5%
CO2). Temperature was continuously monitored and main-
tained at 37 jC (via a thermostatic bath) throughout the
perfusion period (180 min for the control group and 60 min
for the remaining groups); pH was also continuously mon-
itored with a pH electrode and kept stable at 7.35–7.45
during this period. Carvedilol (40 AM) was added to the
Krebs modified solution in the respective experimental
group. Left ventricular pressure and heart rate were recorded
at regular intervals.
After the initial perfusion, all the rat hearts, with the
exception of the control group, were submitted to 120 min
of ischaemia at 37 jC in a solution identical to that of the
perfusion period, but without glucose and carbogen
(replaced by nitrogen).
2.3. Preparation of the biological material
2.3.1. Isolation of rat heart mitochondria
At the end of the perfusion and ischaemia periods, the
mitochondrial fraction from each rat heart was prepared
according to the method described by Rickwood et al.
(1987a). All the parameters of mitochondrial function were
assessed in the isolated mitochondrial fraction.
2.4. Laboratory methods used
2.4.1. Determination of protein concentration
The protein concentration of the mitochondrial fraction
was determined using the biuret colorimetric method (Gor-
nall et al., 1949).
2.4.2. Determination of the mitochondrial membrane
potential
Membrane electrical potential (DW) was determined
through the permanent recording of the distribution of the
lipophilic cation tetraphenylphosphonium (TPP+) across the
inner mitochondrial membrane. This was done with an
electrode sensitive to TPP+ prepared in our laboratory,
according to the principles established by Kamo et al.
(1979). Reactions took place at a constant temperature of
25 jC, in an open and thermostable reaction chamber, using
1 ml of reaction solution (sucrose 130 mM, KCl 50 mM,
MgCl2 5 mM, KH2PO4 5 mM and (N-[2-hydroxyethyl]
piperazine-NV-[2-ethanosulphonic]) acid (HEPES) 5 mM,
pH 7.2), supplemented with 3 AM TPP+ and the mitochon-
drial suspension (volume corresponding to 2 mg of protein,
as determined by the biuret method). The determination of
mitochondrial DW was performed using the method de-
scribed by Muratsugu et al. (1977) and Kamo et al. (1979).
The matrix volume was assumed to be 1.1 Al/mg of protein.
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All the assays were performed at 25 jC, in a closed
reaction chamber, with stable temperature and 1 ml capacity.
Oxygen consumption was evaluated polarographically
with an O2 electrode (Yellow Springs Instruments), Clark
type, connected to a Kipp and Zonen recorder, through a
command unit manufactured at our laboratory. Electrode
calibration was done according to the protocol described by
Rickwood et al. (1987b).
Reactions were initiated by adding the mitochondrial
suspension to the reaction solution (as previously described).
The later addition of the respiratory substrate [glutamate 10
mM +malate 5 mM, succinate 5 mM or ascorbate 5
mM+N,N,NV,NV-tetramethyl-P-phenylenodiamine (TMPD)
0.25 mM] induced an increase in O2 consumption by the
mitochondrial fraction. Respiratory state 3 (characterised by
a higher and faster O2 consumption) was then induced by the
addition of adenosine diphosphate (ADP) 250 nmol (62.5
nmol when using ascorbate/TMPD). After all ADP was
consumed, the reaction returned to a slower velocity, respi-
ratory state 4. Respiratory Control Ratio was evaluated as the
quotient between state 3 and state 4.
2.4.4. Evaluation of the energy charge
The protocol for extraction of the adenine nucleotides
(ATP, ADP and AMP) was as follows: at the end of one
phosphorylation cycle induced by the addition of ADP,
250 Al of the final respiratory medium was collected
(corresponding to 0.5 mg of mitochondrial protein) and
added to 250 Al of HClO4 0.6 M (with 25 mM of EGTA).
Five minutes later, the mixture was agitated in a vortex (to
obtain a protein-free sample) and centrifuged for 2 min at
10,000 g in an Eppendorf centrifuge (at 0 jC). The pellet
was then removed and the supernatant was neutralised
with KOH 3 M+Tris 1.5 M and then centrifuged at
10,000 g for another 2 min. All procedures were con-
ducted at low temperature (0–4 jC). The adenine nucleo-
tides were separated by high-pressure liquid chromatogra-
phy (HPLC), reverse phase (Stocchi et al., 1985), in a
Beckman Gold chromatograph, with a model 126 pump
and a variable UV detector (model 166), controlled by
computer. The detection wavelength was 254 nm, using a
Licrosphere 100 RP-18 column (5 mm) made by Merck.
The protocol used consisted in isocratic elution with
potassium phosphate buffer (100 mM; pH 6.5) and meth-
anol 1%. The flow rate was 1.25 ml/min for 5 min (to
achieve nucleotide separation); the detection limit for each
compound was 3–5 pmol.
The energy charge was determined according to the
following formula: ([ATP] + 0.5*[ADP]/([ATP]+[ADP]+
[AMP])).
2.4.5. Determination of enzyme activity
2.4.5.1. Complex I. The activity of this enzyme complex
was evaluated by spectrofluorometry: complex I converts
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(oxidised nicotinamide dinucleotide), and pyridine nucleo-
tides produce fluorescence at 450 nm, when excited at 366
nm. Disrupted mitochondria (disruption induced by freez-
ing/thawing cycles) do not possess an internal pool of
reduced nucleotides (like NADH). Therefore, the heart
mitochondria obtained by differential centrifugation were
submitted to three cycles of freezing/thawing. Afterwards, a
volume of the mitochondrial fraction corresponding to 0.4
mg of protein (as determined by the biuret method) was
placed in quartz cuvettes containing 2 ml of the buffer
solution (KH2PO4 25 mM+MgCl2 10 mM; pH 7.4) and
KCN 1 mM. Fluorescence emission was determined in a
Perkin Elmer spectrofluorimeter (LS 50B model) at 30 jC;
the reaction was initiated by the addition of NADH 50 AM.
After the emission peak was measured, dodecylubiquinone
162.5 AM was added, with a consequent fall in fluorescence
emission, graphically expressed by a line whose slope
allowed the determination of mitochondrial complex I
activity. In the final phase of each assay, a specific complex
I inhibitor (rotenone 3.8 AM) was added, in order to
guarantee that the previously obtained values were indeed
complex I enzyme activity. Enzyme activity was the differ-
ence between the slopes of the lines before and after
rotenone addition, determined with the FL Winlab software
provided with the spectrofluorimeter. This value is
expressed in arbitrary units.
2.4.5.2. Complexes II–III. In order to evaluate the activity
of complexes II–III, the method described by King (1967)
was used. Enzyme activity (in nmol/min/mg of protein) was
determined with the following equation: AE=[(DAbs)/
19.2]*(1000/Al of mitochondrial suspension)*1000 in
which AE represents the enzyme activity and DAbs repre-
sents the absorbance variation per minute at 550 nm.
Results are expressed as nmol of succinate oxidized/min/
mg protein.
2.4.5.3. Complex IV. For the determination of complex IV
enzyme activity, O2 consumption associated with cyto-
chrome c oxidation by complex IV was measured. Rotenone
(specific inhibitor of complex I) and antimycin A (inhibitor
of complexes II–III) were added to the reaction medium, in
order to guarantee that the O2 consumption was not due to
the activity of other mitochondrial enzyme complexes. This
measurement was made with the technique already used for
the determination of mitochondrial respiratory activity. The
same reaction medium was used, to which rotenone 3 AM,
antimycin A 0.5 Ag, a volume of mitochondrial suspension
corresponding to 0.1 mg of protein and cytochrome c 15 AM
were sequentially added.
The reaction was initiated with 10 Al of Ascorbate 500
mM/TMPD 25 mM, and O2 consumption was registered in
the same way as for the determination of respiratory activity.
O2 consumption was used to determine complex IV enzyme
activity, expressed in nmol O2/min/mg protein.
Fig. 2. Comparison between maximal electrical potential (DW) in the
control, ischaemic and carvedilol-treated hearts, after the addition of the
energy substrate to the reaction medium containing rat heart mitochondria:
al of Pharmacology 482 (2003) 245–2532.4.5.4. ATP synthase. To determine the activity of this
enzyme complex, assays were conducted at 37 jC in an
open reaction chamber under permanent shaking, in a
volume of 2 ml of the reaction medium (sucrose 130 mM,
KCl 60 mM, HEPES 0.5 mM and MgCl2 2.5 mM; pH 7.0).
After 1 min, the time necessary to achieve the desired buffer
temperature, rotenone 3 AM and 0.5 mg mitochondrial
protein were added. The reaction was initiated with ATP-
Mg2 + 2 mM, and pH variations were evaluated continuous-
ly by a protonometric method (Madeira et al., 1974), using a
Crison pH evaluation system consisting of a glass electrode
connected to a Kipp and Zonen recorder. At the end of the
reaction, pH titration was performed, using 10 mM HCl and
KOH. Enzyme activity was calculated using the slope of the
curve for change in pH after the addition of ATPMg2 + and
is expressed in nmol H+/min/mg protein. Oligomycin was
not used because our preparations were essentially devoid of
myofibrils or other cellular debris, as determined by electron
microscopy (data not shown).
2.5. Statistical analysis
Results are presented as meansF standard error (raw
data or expressed as percentage of control), for the number
of results indicated. Results were analyzed using the one-
way ANOVA test. The level of significance used was
P < 0.05.
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ischaemic group.3. Results
Our results showed that oxidative phosphorylation was
very sensitive to ischaemia, as demonstrated by the decrease
in the respiratory control ratio, when compared with the
value obtained for control group mitochondria (2.68F 0.25
vs. 1.51F 0.13; P < 0.05). In the group treated with carve-
dilol, there was no significant improvement in respiratory
control ratio (1.61F 0.08 vs. 1.51F 0.13—that is,
60.1F 3% vs. 56.3F 4.9% in the group submitted to
ischaemia without carvedilol; P= n.s.; Fig. 1).
When glutamate/malate was used as energy substrate,
electrical potential (DW) values decreased significantly inFig. 1. Comparison of respiratory control ratio values in rat heart
mitochondria (control, ischaemic and carvedilol groups) with glutamate/
malate as energy substrate. Values are presented as a ratio.the ischaemic group, when compared to the control group
(209.13F 1.37 mV vs. 186.66F 3.36 mV; P < 0.001); a
similar result was found with succinate (211.32F 3.24
mV vs. 187.23F 4.74 mV; P < 0,05) and ascorbate/TMPD
(209.09F 2.53 mV vs. 189.24F 3.98 mV; P < 0.05). Mito-
chondria from hearts treated with carvedilol 40 AM devel-
oped a significantly higher electrical potential than did
mitochondria from hearts exposed to ischaemia in the
absence of carvedilol. This was observed for all three energy
substrates used: glutamate/malate (95.4F 1.2% in the car-
vedilol group vs. 89.3F 1.6% in the ischaemic group—
201.2F 2.45 mV vs. 186.66F 3.36 mV; P < 0.05), succi-
nate (94.9F 1.2% in the carvedilol group vs. 88.6F 2.2%
in the ischaemic group or 200.73F 2.6 mV vs. 187.23F
4.74 mV; P < 0.05) and ascorbate/TMPD (96.5F 1.4% in
the carvedilol group vs. 90.5F 1.9 in the ischaemic
group—201.87F 2.85 mV vs. 189.24F 3.98 mV; P <
0.05; Fig. 2A–C).
Another parameter evaluated was the amount of time
needed to phosphorylate a fixed amount of ADP (250
nmol)-lag phase. The lower this value is, the quicker the
phosphorylation cycle is completed. We observed a longer
lag phase in the ischaemic group, when compared to control,
not only with glutamate/malate (59.08F 6.82 vs. 127.2F
19.03 s; P < 0.05), but also with succinate (66.46F 6.43 vs.
275.73F 45.99 s; P < 0.05) and ascorbate/TMPD (31.5F
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carvedilol showed, globally, a shortening of the lag phase
time (vs. ischaemic group), but of different magnitude,
depending on the substrate used. When glutamate/malate
was used, the lag phase decrease was minimal (204.5
F 12.7%–120.82F 7.53 s– in the carvedilol group vs.
215.3F32.2%–127.2F 19.03 s–in the ischaemic group;
P= n.s.). It was greater, although still non-significant, with
succinate (337.2F 24.6%–224.54F 15.99 s–in the carve-
dilol group vs. 414.9F 69.2%–275.73F 45.99 s–in the
ischaemic group; P= n.s.) and only became significant when
complex IV was specifically activated with ascorbate/
TMPD (90.9F 13.4%–28.64F 4.23 s–in the carvedilol
group vs. 198.1F 6.7%–62.4F 11.63 s–in the ischaemic
group; P < 0.05; Fig. 3A–C).
As already mentioned, the energy charge ([ATP] +
0.5*[ADP]/([ATP]+[ADP]+[AMP])) was calculated forFig. 3. Comparison of the phosphorilation lag phase in the three
experimental groups (control, ischaemic and carvedilol) for each of the
energy substrates studied, after the addition of 250 nmol of ADP (62.5
when using ascorbate/TMPD) to the medium containing rat heart
mitochondria and the substrate: (A) glutamate/malate; (B) succinate; (C)
ascorbate/TMPD. *P< 0.05 vs. the ischaemic group.
Fig. 4. Comparison of the energy charge values (obtained by HPLC) in the
three experimental groups (control, ischaemic and carvedilol) for each of
the energy substrates studied, after the addition of 250 nmol of ADP (62.5
when using ascorbate/TMPD) to the medium containing rat heart
mitochondria and the energy substrate: (A) glutamate/malate; (B) succinate;
(C) ascorbate/TMPD. *P< 0.05 vs. the ischaemic group.each substrate used. The ischaemic group had a lower
energy charge, when compared to the control group,
regardless of the energy substrate evaluated: glutamate/
malate (0.965F 0.005 vs. 0.89F 0.04; P= n.s.), succinate
(0.79F 0.051 vs. 0.65F 0.01; P < 0.05) or ascorbate/
TMPD (0.7F 0.04 vs. 0.59F 0.02; P= n.s.); however,
this difference only reached statistical significance when
succinate was used as substrate. The energy charge of
mitochondria from hearts treated with carvedilol was not
significantly different from that of mitochondria from the
ischaemic group when glutamate/malate (86F 4.1%–
0.83F 0.04–in the carvedilol group vs. 92.2F 4.1%–
0.89F 0.04–in the ischaemic group; P= n.s.) was used
as substrate. However, when using succinate, the group
treated with carvedilol was able to generate a significantly
higher energy charge (96.2F3.8%–0.76F 0.03–in the
carvedilol group vs. 82.3F1.3%–0.65F 0.01– in the
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ascorbate/TMPD was used (98.6F4.3%–0.69F 0.03–in
the carvedilol group vs. 84.3F 2.9%–0.59F 0.02–in the
ischaemic group; P < 0.05; Fig. 4A–C).
The activity of the respiratory chain complexes I, II–III,
IV and ATP synthase was also evaluated. A statistically
significant difference (P < 0.05) was found between ischae-
mic and control groups for all four enzyme complexes
evaluated (complex I: 100 vs. 63.23F 5.18 arbitrary units;
complexes II– III: 14,370F 1174 vs. 8592F 663 nmol
succinate oxidized/min/mg protein; complex IV: 853F 66
vs. 608F 58 nmol O2 consumed/min/mg protein; ATP
synthase: 795F 75 vs. 426F 35 nmol H+ released/min/
mg protein). The carvedilol group showed a trend towards
a higher activity for all complexes, although without
reaching statistical significance. The mean values obtained
were as follows: complex I 66.2F 8.8 arbitrary units in the
carvedilol group vs. 63.23F 5.18 arbitrary units in the
ischaemic group (P= n.s.); complexes II–III 66F 13%
(9485F 1863 nmol succinate oxidized/min/mg protein) in
the carvedilol group vs. 59.8F 4.6% (8592F 663 nmol
succinate oxidized/min/mg protein) in the ischaemic group
(P= n.s.); complex IV 76.1F 6.1% (649F 52 nmol O2
consumed/min/mg protein) in the carvedilol group vs.
71.3F 6.8% (608F 58 nmol O2 consumed/min/mg pro-
tein) in the ischaemic group (P= n.s.); and ATP synthase
63.1F 7.3% (502F 58 nmol H+ released/min/mg protein)Fig. 5. Comparison of the values of the enzyme activity of rat heart mitochondria o
of the complexes studied (I, II – III, IV e ATP synthase), in the presence of the sub
respectively): (A) complex I; (B) complexes II– III; (C) complex IV; (D) ATP syin the carvedilol group vs. 53.6F 4.4% (426F 35 nmol H+
released/min/mg protein) in the ischaemic group (P= n.s.;
Fig. 5A–D).4. Discussion
This work was performed to study the impact of carve-
dilol on the mitochondrial function of rat hearts exposed to
acute ischaemia. Our working hypothesis was that carvedi-
lol could prevent mitochondrial damage, possibly by means
of its intrinsic antioxidant properties. The chosen carvedilol
concentration was within the range of doses shown in the
literature to have maximal antioxidant effects without being
toxic to mitochondria (Abreu et al., 2000). The results
showed that this drug had a different impact on the mito-
chondrial function parameters assessed.
Regarding the activity of the mitochondrial respiratory
chain and coupling of oxidative phosphorylation, the direct
effect of carvedilol was not significant. In fact, respiratory
control ratio values obtained in the carvedilol group were
similar to those obtained for the ischaemic group. The same
was true for the enzyme activity of the respiratory chain
components: values obtained for the carvedilol group were
not significantly different from those for the ischaemic
group. When analysing these results, it is important to
remember that, when using an experimental model of acutef the three experimental groups (control, ischaemic and carvedilol), for each
strate of each complex (NADH, succinate, ascorbate/TMPD or ATP-Mg2 +,
nthase. *P < 0.05 vs. the ischaemic group.
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ing 180 min), a significant deterioration of mitochondrial
function is to be expected when compared with that of
control hearts whose mitochondria are isolated immediately
after the animal is killed (Crestanello et al., 2002a,b).
Therefore, a direct comparison between the respiratory
control ratio values obtained in control mitochondria and
in mitochondria from hearts not submitted to perfusion (or
only submitted to short-term perfusion) is not possible, as
the conditions are not equivalent.
The most favourable effects of carvedilol were on the
functional status of the phosphorylation system. Carvedilol
was able to decrease the length of the lag phase and to
increase the mitochondrial energy charge. This positive
impact on cardiac mitochondrial phosphorylation during
ischaemia (making it faster—shorter lag phase—and leading
to higher ATP production—higher energy charge), allowed
it to generate greater energy reserves, which are important to
obtain a better control of the mitochondrial transmembrane
electrochemical gradient, resulting in a higher electrical
potential (DW) in the carvedilol group, regardless of the
substrate used.
In experimental models involving non-ischaemic hearts,
carvedilol induced a slight decrease in mitochondial electri-
cal potential, which the authors attributed to a protonopho-
retic effect (Abreu et al., 2000; Oliveira et al., 2000);
however, it should be noted that it has not been demon-
strated that such an effect also occurs during ischaemia. An
alternative hypothesis is that, during ischaemia, this proto-
nophoretic effect can be supplanted by the already demon-
strated antioxidant effect of carvedilol, allowing the
protection of the mitochondrial membranes from oxidation
and lipoperoxidation (Oliveira et al., 2001; Rolo et al., 2001;
Santos and Moreno, 2001).
However, results obtained in our experimental model can
only be partially explained by the antioxidant effect of
carvedilol. It is known that the production of reactive
oxygen species during isolated ischaemia (not followed by
reperfusion) is modest (Jassem et al., 2002), and that when
oxygen is reintroduced in the system (during reperfusion),
the production of reactive oxygen species increases sharply.
So, in a model of ischaemia without reperfusion, a positive
impact on cardiac mitochondrial function can not be attrib-
uted solely to an antioxidant action. Recent experimental
work performed with animal models of coronary stenosis
and coronary occlusion suggested that, in acute ischaemia
settings without reperfusion, carvedilol was unable to pre-
vent ventricular remodelling (a feature usually related to its
antioxidant properties) (Yaoita et al., 2002).
When considered globally, the results obtained for the
carvedilol group in this experimental protocol allow us to
suggest that, during acute prolonged ischaemia (as in the
ischaemic and carvedilol groups), the protective effect of
carvedilol on the mitochondrial respiratory chain (via its
antioxidant activity) may not be pronounced. Instead, car-
vedilol had a protective effect on the phosphorylationsystem, thus allowing a greater and faster generation of
ATP as soon as oxygen became available (as in our in vitro
system for measuring mitochondrial function), which is
essential to the preservation of cardiac mitochondrial func-
tion (and, lato senso, to the survival of cardiomyocytes) in
the context of an ischaemic insult.
Our data are concordant with the results of large clinical
trials that assessed the impact of antioxidant drugs in the
treatment of myocardial ischaemia. To date these clinical
trials have been unable to prove a positive effect on
mortality in patients with coronary artery disease (GISSI-
Prevenzione Investigators (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Mioca´rdico), 1999; Heart
Protection Study Collaborative Group, 2002; The Heart
Outcomes Prevention Evaluation Study Investigators,
2000; Stephens et al., 1996). What really distinguishes
carvedilol from these drugs is its ability to generate more
ATP without increasing O2 consumption. We propose that
carvedilol may act during ischemia to protect the phosphor-
ylation system, so that the system can produce large
amounts of ATP quickly, as soon as the respiratory chain
is again exposed to oxygen, thus solving the main problem
accompanying ischaemia—the shortage of energy for myo-
cyte recovery after reperfusion.
Our work clearly shows, for the first time, that during
episodes of acute myocardial ischaemia the cardioprotective
effect of carvedilol may be due to a positive impact on the
mitochondrial phosphorylation system, allowing a faster and
greater production of energy during the later reperfusion
phase. The extra energy supply is essential to the preserva-
tion of cellular viability during the reperfusion phase that
follows the ischaemic insult. This represents a clear differ-
ence from ischaemia/reperfusion settings, where carvedilol
seems to act mainly as an antioxidant (Oliveira et al., 2002).
This knowledge allows a better understanding of the com-
plex mechanisms behind the positive impact of carvedilol in
patients with coronary artery disease.Acknowledgements
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